Noxopharm Successfully Raises $1.5 Million via Placement
Filed with ASX · · 5 pages · English
Summary by 6ix AI
Noxopharm Ltd. has announced a successful equity raising of funds through a placement to advance its clinical program for SOF-SKN. Proceeds will support various activities including an extension study for cutaneous lupus erythematosus and other research and development efforts.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Noxopharm
- Voluntary Suspension
- Trading Halt
- Novel oligonucleotides data presented at Options Conference
- Appendix 4E - Preliminary Financial Report
- New preclinical data supports immuno-oncology approach
Later from Noxopharm
All Noxopharm news releasesFollow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm